| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal: TA870 Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma |
|
Medicine details |
|
| Medicine name | ixazomib citrate (Ninlaro®) |
| Formulation | 2.3 mg, 3 mg, 4 mg capsule |
| Reference number | 1777 |
| Indication | In combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy |
| Company | Takeda UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 07/10/2016 |
| NICE guidance | |